Biological therapies that antagonize specific molecules have demonstrated efficacy in inflammatory bowel diseases, but infections resulting from systemic immunosuppression underscore the need for safer therapies. The objective of this investigation was to determine if antagonism of the α4β7 integrin would exclusively yield gut-selective antiinflammatory activity in primates.
A series of experiments were conducted to investigate potential intra- and extraintestinal effects in healthy nonhuman primates dosed repeatedly with the α4β7-exclusive antagonist vedolizumab (former versions: MLN0002, MLN02, LDP-02) for 4, 13, and 26 weeks.
These data demonstrate that blocking the α4β7 integrin exclusively yields gut-selective antiinflammatory activity in primates. (Inflamm Bowel Dis 2012;)